Breaking News From ADA 2020
This page was last updated at 9:20am pm PT June 16, 2020.
Editor’s Note: this article will be updated regularly with breaking news and announcements during the course of the ADA Scientific Sessions Conference. Check back often! Follow along on twitter at #ADA2020
Tuesday, June 16, 2020
- A 22-year follow up on the Diabetes Prevention Program Outcomes Study (DPPOS) indicates a continued significant reduction in the participants’ risk of developing Type 2 diabetes. The trial, which was conducted from 1996 to 2001, sought to determine the success of either an intensive lifestyle change program or treatment with metformin to prevent or delay the development of Type 2 diabetes in those who were high-risk. Though Metformin is an approved drug to treat Type 2 diabetes, it is not approved for use in the United States to prevent the disease. However, it is approved in other countries. 22 years later, 75 percent of the participants, who are still alive, have continued to be evaluated. Since the start of the study, individuals in the lifestyle intervention group had a reduced risk of 25 percent of developing Type 2 diabetes. Those in the metformin group had an 18 percent reduced risk. The DPPOS study is the largest prevention and longest duration study that continues to actively follow its participants.
- New rapid-acting insulin Lyumjev from Lilly receives FDA approval for Type 1 and Type 2 diabetes. More information to come on the specific time to action, prescribing information indicates that it should be taken at meals or up to twenty minutes following meals, and is designed to manage after-meal spikes better than Humalog or similar insulins. It is not yet approved for use in insulin pumps or for children.
Monday, June 15 2020
- Results from the Trends in Glycemic Control among Youth with Diabetes: The SEARCH for Diabetes in Youth Study revealed that despite the increased availability of diabetes technology, new therapies, and more aggressive control targets, today’s young adults and youth have worse glycemic control than previous youth and young adult groups from 2002-2007. Data shows these new groups currently aren’t meeting A1C recommendations. Youth and young adults with Type 1 diabetes had an average A1c with 8.7 percent, while those with Type 2 diabetes had an estimated average A1c of 8.5 percent. “Given the evidence highlighting the benefits of tight glycemic control, this study reinforces the need for interventions that combine the use of diabetes technology with effective behavioral and social approaches to improve A1C levels,” said the study’s lead author Faisal Malik, MD, MSHS, assistant professor of pediatrics at the University of Washington School of Medicine, investigator at the Center for Child Heath, Behavior and Development at Seattle Children’s Research Institute, and a pediatric endocrinologist at Seattle Children’s Hospital.
- Analysis of data from the large international DAPA-HF trial showed that the SGLT-2 inhibitor, dapagliflozin, may reduce the onset of Type 2 diabetes when used in patients with heart failure. Data showed that dapagliflozin reduced new-onset diabetes by 32 percent with 4.9 percent of patients developing Type 2 diabetes compared to 7.1 percent in the placebo group. Participants who developed diabetes had higher average A1C levels, greater body mass index, and lower eGFR at the beginning of the study than those who did not develop diabetes. SGLT-2 inhibitors are oral agents designed to help lower blood glucose by preventing glucose from being absorbed in the kidney. The end result is glucose is excreted through urine.
- Abbott announced that the FDA has approved the FreeStyle Libre 2 System – it is approved for adults and children 4 and up in the United States. The FreeStyle Libre 2 is a 14 day CGM system that transmits data every minute and now includes customizable high and low alerts without the need to scan the device. The Abbott announcement says it will be “a third of the cost of other CGMs.”
Sunday, June 14 2020
- A new study shows minority patients in states with Medicaid expansion experience fewer leg amputations. Data revealed the odds of a major amputation among non-white Medicaid beneficiaries decreased by 17.3 percent in early-adopter states and increased by 1 percent in non-adopter states. The research also indicated patients were seeking medical treatment earlier and were able to prevent amputations. Existing research shows more than half of people with diabetes-related lower-extremity amputation die within five years, a rate higher than most cancer-related deaths. It’s estimated up to one-third of patients with diabetes will develop a foot ulcer, the most common reason for foot and leg amputation.
Saturday, June 13 2020
- A rural telehealth program, Advanced Comprehensive Diabetes Care (ACDC) improved Type 2 diabetes management in people with mismanaged diabetes. The intervention resulted in an average 1.0 percent improvement in A1C and at least 2.0 percent improvement in those who achieved half of the scheduled healthcare provider contacts. The project was implemented using three elements: telemonitoring, self-management support, and medication management.
- Eli Lilly and Company presented real-world data that showed at a 6-month follow-up, Trulicity (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections with semaglutide and exenatide (BCise pen) in people with Type 2 diabetes new to GLP-1 receptor agonist (RA) treatment. Fewer patients also discontinued Trulicity compared to semaglutide and exenatide.
- Medtronic presented data on its extended wear infusion set with the ability to be used for up to 7 days. Clinical studies on multiple infusion set platforms demonstrated that the Medtronic Extended infusion set is safe and effective for up to 7 days, more than twice as long as current Medtronic three-day infusion sets. This new infusion set aims to extend patient wear time by maintaining insulin stability and using new adhesive technology.
- A nationwide study from France showed overall DKA rates were reduced in the year following FreeStyle Libre system initiation by 52% for patients with T1D and 47% for patients with T2D. The results were expectedly even more impressive for those who had not been monitoring their blood sugar prior to (60% reduction in T1D, 51% in T2D).
- Additionally, new late-breaking data demonstrated use of its FreeStyle Libre system is associated with significant reduction in HbA1c levels for people living with Type 2 diabetes on either long-acting insulin or non-insulin therapy.
Friday, June 12 2020
- Medtronic presented results from its U.S. pivotal trial of its investigational MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system. Results of the 90-day showed improved A1C, Time in Range, and higher user satisfaction scores.
- Insulet also presented the results of their pre-pivotal trial of Omnipod 5, powered by Horizon. Omnipod 5 demonstrated improved Time in Range, A1C, and 97% of time spent in closed loop. The pivotal trial for the device is currently underway, expecting to ship in the second half of 2021 in the US.
Thursday, June 11 2020
- Mylan and Biocon announced that the FDA has approved Semglee™ (insulin glargine injection), in vials and pre-filled pens for patients with Type 1 and Type 2 diabetes. Semglee has an identical amino acid sequence to Sanofi’s Lantus and the biosimilar drug is approved for the same indications.
- Medtronic announced CE Marking (European Approval) of its MiniMed™ 780G system, a next generation closed loop insulin pump system. The 780G system enables the personalization of glucose goals with an adjustable target setting as low as 100 mg/dL, and is expected to begin shipping this Fall in select countries in Europe.
- In a press release previewing Insulet’s ADA 2020, the company formally announced that their next generation closed loop system — previously known as Omnipod Horizon — has been rebranded as Omnipod® 5 Automated Glucose Control System, Powered by Horizon™ (Omnipod 5 for short).
Click here for complete coverage of ADA 2020 from Beyond Type 2.